A glaucoma drug developed by Aerie Pharmaceuticals (AERI) is currently under review by FDA regulators at the agency’s Rockville, Md., campus, but the decision to approve or reject more likely hinges on the rehabilitation of a dysfunctional manufacturing facility located 900 miles to the south in Tampa, Fla.

Time and circumstances don’t work in Aerie’s favor. The manufacturing facility where Aerie’s drug Rhopressa is made is owned by Bausch & Lomb, a unit of troubled specialty pharmaceuticals firm Valeant Pharmaceuticals (VRX). The plant has a long history of FDA quality control violations Bausch & Lomb can’t seem to fix.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy